Digene Agrees To Pay $16M Plus Royalties To Settle Enzo Biochem Patent Suit
Medical device maker Digene Corp., which markets a DNA-based test for cervical cancer, has agreed to pay Enzo Biochem $16 million, plus guaranteed royalty payments, to settle a patent-infringement suit over...To view the full article, register now.
Already a subscriber? Click here to view full article